Benchmark Holdings plc has released its unaudited Q4 results for the three months ended 30 September 2023. The company reported revenues from continuing operations of £36.6m, a 14% decrease from the prior year. The Genetics segment saw a strong performance in salmon egg sales, with revenues 6% below Q4 FY22. The Advanced Nutrition segment also performed well, despite challenging conditions in the global shrimp markets, with revenues 9% below the prior year. However, the Health segment saw a significant decline in revenues, which were 53% below Q4 FY22, due to a delay in the peak season for sea lice treatments in Norway. The company has experienced an increase in sales of Ectosan® Vet and CleanTreat® post period-end. Adjusted EBITDA from continuing operations, excluding fair value movements from biological assets, was £9.2m, slightly lower than the previous year. Benchmark Holdings had cash and cash equivalents of £29.3m and available liquidity of £41.5m as of 27th November. The company also highlighted several operational highlights, including the launch of Snapp-Art, an AI-enabled tool that allows customers to count and qualify Artemia accurately and efficiently. Benchmark Holdings also announced the integration of its salmon and shrimp activities under new leadership, which is expected to create commercial synergies and efficiencies. The company obtained MSC certification for the Artemia harvested from the Great Salt Lakes and divested its tilapia breeding business. In terms of current trading and outlook, Benchmark Holdings reported a good start to the year and positive momentum in all business areas. The company has good visibility of revenues in salmon genetics and early indications of improvement in the shrimp markets. There has been an increase in sea lice treatments post period-end, and the company expects normal seasonality. Benchmark Holdings aims to strengthen its unique position in the aquaculture biotechnology industry, which is structurally growing driven by megatrends.